Mediprogen Teams Up With Moolec To Innovate In The Global Cosmetics Market

In a significant move within the biotechnology and cosmetics sectors, Mediprogen Inc. has entered into a strategic partnership with Moolec Science S.A., a frontrunner in Molecular Farming. This collaboration, formalized through a non-binding Memorandum of Understanding (MOU), aims to harness Moolec's innovative Piggy Sooy™ technology for applications in cosmetics and other non-food markets globally. This partnership marks a pivotal step for Mediprogen in leveraging advanced biotechnological methods to enhance its product offerings.

Ph.D. Donghern Kim, Chief Executive Officer of Mediprogen, expressed enthusiasm about the collaboration's potential to significantly impact the company's market strategy, particularly in the cosmetics sector. The industry is projected to grow from $63.59 billion in 2023 to an estimated $114.32 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 8.7%. Dr. Kim emphasized the role of Plant Molecular Farming technology in accelerating the development and market introduction of their products.

Moolec Science's expertise and achievements in Molecular Farming, especially their work with genetically modified soybeans and the patented Piggy Sooy™ product, were highlighted by Dr. Kim as critical factors for this partnership. He pointed out the mutual benefits of combining Mediprogen's ambitions with Moolec's technological advancements and regulatory successes.

The MOU between Mediprogen and Moolec outlines plans for a collaborative research project that is expected to lead to a formal commercial agreement. This agreement will focus on the development, manufacturing, and commercialization of specialized non-food molecules derived from genetically engineered soybeans, primarily for use in the cosmetics and skincare industries.

Mediprogen Inc., a plant biotech venture, specializes in producing valuable cosmetic and pharmaceutical proteins from biotech soybean seeds. Utilizing various plant biotechnology techniques, such as optimizing gene expression vectors and codon usage, Mediprogen aims to achieve protein productivity of more than 1% (w/w) seed weight.

This partnership between Mediprogen and Moolec Science S.A. represents a forward-thinking approach to combining biotechnology with cosmetic applications, setting a new standard for innovation in both fields. As these two companies embark on their collaborative journey, the potential for creating advanced solutions that cater to the growing demands of the cosmetics industry is immense.